Expression of ADAM-9 mRNA and protein in human breast cancer

International Journal of Cancer

Volumn 105, Issue 6, 2003, Pages 754-761

  O'Shea, Caroline ^a,b   McKie, Norman ^c   Buggy, Yvonne ^a   Duggan, Catherine ^d   Hill, Arnold D K ^a   McDermotti, Enda ^a   O'Higgins, Niall ^a   Duffy, Michael J ^a,b  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

^b ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^c NEWCASTLE UNIVERSITY   (United Kingdom)

^d IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

ADAM 9, HER 2 neu; ADAMs; Breast cancer; Metastasis

Indexed keywords

DISINTEGRIN; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; MESSENGER RNA; METALLOPROTEINASE; PROTEIN ADAM 9; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BREAST CANCER; FIBROADENOMA; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; ONCOGENE NEU; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TISSUE DISTRIBUTION;

ADAM PROTEINS; BLOTTING, WESTERN; BREAST; BREAST NEOPLASMS; CARCINOMA; DISINTEGRINS; FEMALE; FIBROADENOMA; HUMANS; MEMBRANE PROTEINS; METALLOENDOPEPTIDASES; MIDDLE AGED; MUSCLE PROTEINS; PROGNOSIS; RNA, MESSENGER; RNA, NEOPLASM; TISSUE DISTRIBUTION; TUMOR CELLS, CULTURED;

EID: 0013067947     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.11161     Document Type: Article

References (47)

1. Zetter BR. Angiogenesis and tumor metastasis. Annu Rev Med 1998; 49:407-24.
2. Duffy MJ. The biochemistry of metastasis. Adv Clin Chem 1996;32:135-66.
3. Duffy MJ. The role of proteolytic enzymes in cancer invasion and metastasis. Clin Exp Metastasis 1992;10:145-55.
4. Andreasen PA, Kjoller L, Christensen L, Duffy MJ. The urokinasetype plasminogen activator system in cancer metastasis: a review. Int J Cancer 1997;72:1-22.
5. Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM. Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol 2000;18:1135-49.
6. Duffy MJ. Proteases as prognostic markers in cancer. Clin Cancer Res 1996;2:613-8.
7. Ponta H, Sleeman J, Herrlich P. Tumor metastasis formation: cellsurface proteins confer metastasis-promoting or -suppressing properties. Biochim Biophys Acta 1994;1198:1-10.
8. Parker C, Rampaul RS, Pinder SE, Bell JA, Wencyk PM, Blamey RW, Nicholson RI, Robertson JF. E-cadherin as a prognostic indicator in primary breast cancer. Br J Cancer 2001;85:1958-63.
9. Maguire TM, Shering SG, McDermott EW, O'Higgins N, Fennelly JJ, Crown J, Duffy MJ. Assay of E-cadherin by ELISA in human breast cancers. Eur J Cancer 1997;33:404-8.
10. Berx G, Cleton-Jansen AM, Nollet F, de Leeuw WJ, van de Vijver M. Cornelisse C, van Roy F. E-cadherin is a tumour/invasion suppressor gene mutated in human lobular breast cancers. Embo J 1995;14:6107-15.
11. Friedrichs K, Ruiz P, Franke F, Gille I, Terpe HJ, Imhof BA. High expression level of alpha 6 integrin in human breast carcinoma is correlated with reduced survival. Cancer Res 1995;55:901-6.
12. Varner JA, Cheresh DA. Integrins and cancer. Curr Opin Cell Biol 1996;8:724-30.
13. Wolfsberg TG, Primakoff P, Myles DG, White JM. ADAM, a novel family of membrane proteins containing a disintegrin and metalloprotease domain: multipotential functions in cell-cell and cell-matrix interactions. J Cell Biol 1995;131:275-8.
14. Stone AL, Kroeger M, Sang QX. Structure-function analysis of the ADAM family of disintegrin-like and metalloproteinase-containing proteins (review). J Protein Chem 1999;18:447-65.
15. Primakoff P, Myles DG. The ADAM gene family: surface proteins with adhesion and protease activity. Trends Genet 2000;16:83-7.
16. Black RA, White JM. ADAMs: focus on the protease domain. Curr Opin Cell Biol 1998;10:654-9.
17. Roghani M, Becherer JD, Moss ML, Atherton RE, Erdjument-Bromage H, Arribas J, Blackburn RK, Weskamp G, Tempst P, Blobel CP. Metalloprotease-disintegrin MDC9: intracellular maturation and catalytic activity. J Biol Chem 1999;274:3531-40.
18. Schwettmann L, Tschesche H. Cloning and expression in Pichia pastoris of metalloprotease domain of ADAM 9 catalytically active against fibronectin. Protein Expr Purif 2001;21:65-70.
19. Izumi Y, Hirata M, Hasuwa H, Iwamoto R, Umata T, Miyado K, Tamai Y, Kurisaki T, Sehara-Fujisawa A, Ohno S, Mekada E. A metalloprotease-disintegrin, MDC9/meltrin-gamma/ADAM9 and PKCdelta are involved in TPA-induced ectodomain shedding of membrane-anchored heparin-binding EGF-like growth factor. Embo J 1998;17:7260-72.
20. Higashiyama S, Abraham JA, Miller J, Fiddes JC, Klagsbrun M. A heparin-binding growth factor secreted by macrophage-like cells that is related to EGF. Science 1991;251:936-9.
21. Nath D, Slocombe PM, Webster A, Stephens PE, Docherty AJ, Murphy G. Meltrin gamma(ADAM-9) mediates cellular adhesion through alpha(6)beta(1)integrin, leading to a marked induction of fibroblast cell motility. J Cell Sci 2000;113:2319-28.
22. Zhou M, Graham R, Russell G, Croucher PI. MDC-9 (ADAM-9/ Meltrin gamma) functions as an adhesion molecule by binding the alpha(v)beta(5) integrin. Biochem Biophys Res Commun 2001;280:574-80.
23. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162:156-9.
24. Allen RW, Trach KA, Hoch JA. Identification of the 37-kDa protein displaying a variable interaction with the erythroid cell membrane as glyceraldehyde-3-phosphate dehydrogenase. J Biol Chem 1987;262:649-53.
25. Crofford LJ, Sano H, Karalis K, Friedman TC, Epps HR, Remmers EF, Mathern P, Chrousos GP, Wilder RL. Corticotropin-releasing hormone in synovial fluids and tissues of patients with rheumatoid arthritis and osteoarthritis. J Immunol 1993;151:1587-96.
26. Langton KP, McKie N, Curtis A, Goodship JA, Bond PM, Barker MD, Clarke M. A novel tissue inhibitor of metalloproteinases-3 mutation reveals a common molecular phenotype in Sorsby's fundus dystrophy. J Biol Chem 2000;275:27027-31.
27. Liao J, Xu X, Wargovich MJ. Direct reprobing with anti-beta-actin antibody as an internal control for western blotting analysis. Biotechniques 2000;28:216-8.
28. Gilpin BJ, Loechel F, Mattei MG, Engvall E, Albrechtsen R, Wewer UM. A novel, secreted form of human ADAM 12 (meltrin alpha) provokes myogenesis in vivo. J Biol Chem 1998;273:157-66.
29. Wu E, Croucher PI, McKie N. Expression of members of the novel membrane linked metalloproteinase family ADAM in cells derived from a range of haematological malignancies. Biochem Biophys Res Commun 1997;235:437-42.
30. Yavari R, Adida C, Bray-Ward P, Brines M, Xu T. Human met alloprotease-disintegrin Kuzbanian regulates sympathoadrenal cell fate in development and neoplasia. Hum Mol Genet 1998;7:1161-7.
31. Iba K, Albrechtsen R, Gilpin BJ, Loechel F, Wewer UM. Cysteinerich domain of human ADAM 12 (meltrin alpha) supports tumor cell adhesion. Am J Pathol 1999;154:1489-501.
32. Emi M, Katagiri T, Harada Y, Saito H, Inazawa J, Ito I, Kasumi F, Nakamura Y. A novel metalloprotease/disintegrin-like gene at 17q21.3 is somatically rearranged in two primary breast cancers. Nat Genet 1993;5:151-7.
33. Masui T, Hosotani R, Tsuji S, Miyamoto Y, Yasuda S, Ida J, Nakajima S, Kawaguchi M, Kobayashi H, Koizumi M, Toyoda E, Tulachan S, et al. Expression of METH-1 and METH-2 in pancreatic cancer. Clin Cancer Res 2001;7:3437-43.
34. Mahimkar RM, Baricos WH, Visaya O, Pollock AS, Lovett DH. Identification, cellular distribution and potential function of the metalloprotease-disintegrin MDC9 in the kidney. J Am Soc Nephrol 2000;11:595-603.
35. Weskamp G, Kratzschmar J, Reid MS, Blobel CP. MDC9, a widely expressed cellular disintegrin containing cytoplasmic SH3 ligand domains. J Cell Biol 1996;132:717-26.
36. Hanemaaijer R, Verheijen JH, Maguire TM, Visser H, Toet K, McDermott E, O'Higgins N, Duffy MJ. Increased gelatinase-A and gelatinase-B activities in malignant vs. benign breast tumors. Int J Cancer 2000;86:204-7.
37. Chenard MP, O'Siorain L, Shering S, Rouyer N, Lutz Y, Wolf C, Basset P, Bellocq JP, Duffy MJ. High levels of stromelysin-3 correlate with poor prognosis in patients with breast carcinoma. Int J Cancer 1996;69(6):448-51.
38. Duffy MJ, Blaser J, Duggan C, McDermott E, O'Higgins N, Fennelly JJ, Tschesche H. Assay of matrix metalloproteases types 8 and 9 by ELISA in human breast cancer. Br J Cancer 1995;71:1025-8.
39. Remacle AG, Noel A, Duggan C, McDermott E, O'Higgins N, Foidart JM, Duffy MJ. Assay of matrix metalloproteinases types 1, 2, 3 and 9 in breast cancer. Br J Cancer 1998;77:926-31.
40. Nakopoulou L, Giannopoulou I, Gakiopoulou H, Liapis H, Tzonou A, Davaris PS. Matrix metalloproteinase-1 and -3 in breast cancer: correlation with progesterone receptors and other clinicopathologic features. Hum Pathol 1999;30:436-42.
41. Pacheco MM, Mourao M, Mantovani EB, Nishimoto IN, Brentani MM. Expression of gelatinases A and B, stromelysin-3 and matrilysin genes in breast carcinomas: clinico-pathological correlations. Clin Exp Metastasis 1998;16:577-85.
42. Elston CW, Ellis IO, Pinder SE. Pathological prognostic factors in breast cancer. Crit Rev Oncol Hematol 1999;31:209-23.
43. Tabar L, Fagerberg G, Chen HH, Duffy SW, Gad A. Tumour development, histology and grade of breast cancers: prognosis and progression. Int J Cancer 1996;66:413-9.
44. Isaacs C, Stearns V, Hayes DF. New prognostic factors for breast cancer recurrence. Semin Oncol 2001;28:53-67.
45. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-82.
46. Sagane K, Ohya Y, Hasegawa Y, Tanaka I. Metalloproteinase-like, disintegrin-like, cysteine-rich proteins MDC2 and MDC3: novel human cellular disintegrins highly expressed in the brain. Biochem J 1998;334:93-8.
47. Wolfsberg TG, Straight PD, Gerena RL, Huovila AP, Primakoff P, Myles DG, White JM. ADAM, a widely distributed and developmentally regulated gene family encoding membrane proteins with a disintegrin and metalloprotease domain. Dev Biol 1995;169:378-83.